TY - JOUR
T1 - Cysteamine re-establishes the clearance of Pseudomonas aeruginosa by macrophages bearing the cystic fibrosis-relevant F508del-CFTR mutation
AU - Ferrari, Eleonora
AU - Monzani, Romina
AU - Villella, Valeria R.
AU - Esposito, Speranza
AU - Saluzzo, Francesca
AU - Rossin, Federica
AU - D'Eletto, Manuela
AU - Tosco, Antonella
AU - De Gregorio, Fabiola
AU - Izzo, Valentina
AU - Maiuri, Maria C.
AU - Kroemer, Guido
AU - Raia, Valeria
AU - Maiuri, Luigi
N1 - Funding Information:
We thank Dr Bob Scholte, Erasmus Medical Center Rotterdam, The Netherlands, who provided Cftrtm1EUR (F508del (FVB/129) mice (European Economic Community European Coordination Action for Research in Cystic Fibrosis program EU FP6 SHM-CT-2005-018932), Dr Beth Levine, Center for Autophagy Research, Department of Internal Medicine, UT Southwestern Medical Center, Dallas, USA, and Dr Francesco Cecconi, University of Tor Vergata, Rome, Italy, who provided C57BL/6J background Becn1+/-mice, Dr EM Bruscia, Yale University School of Medicine, who provided GFP-labelled P. aeruginosa. This study was supported by The European Institute for Research in Cystic Fibrosis (IERFC) non-profit foundation, Regional Cystic Fibrosis Associations of Campania, Sicilia, Lazio, Puglia, Piemonte (to Dr L Maiuri, Dr Raia), E-Rare (Rescue CFTR preclinic) (to Dr L Maiuri and Dr. Kroemer); Telethon (#GGP12128) (to Dr L Maiuri, Dr Raia, Dr MC Maiuri), Agence National de la Recherche (ANR) - Projetsblancs; ANR under the frame of E-Rare-2, the ERA-Net for Research on Rare Diseases; Association pour la recherche sur le cancer (ARC); Cancéropôle Ile-de-France; Institut National du Cancer (INCa); Fondation Bettencourt-Schueller; Fondation de France; Fondation pour la Recherche Médicale (FRM); the European Commission (ArtForce); the European Research Council (ERC); the LabEx Immuno-Oncology; the SIRIC Stratified Oncology Cell DNA Repair and Tumor Immune Elimination (SOCRATE); the SIRIC Cancer Research and Personalized Medicine (CARPEM); and the Paris Alliance of Cancer Research Institutes (PACRI) (all to Dr Kroemer).
PY - 2017/1/1
Y1 - 2017/1/1
N2 - Cystic fibrosis (CF), the most common lethal monogenic disease in Caucasians, is characterized by recurrent bacterial infections and colonization, mainly by Pseudomonas aeruginosa, resulting in unresolved airway inflammation. CF is caused by mutations in the gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein, which functions as a chloride channel in epithelial cells, macrophages, and other cell types. Impaired bacterial handling by macrophages is a feature of CF airways, although it is still debated how defective CFTR impairs bacterial killing. Recent evidence indicates that a defective autophagy in CF macrophages leads to alterations of bacterial clearance upon infection. Here we use bone marrow-derived macrophages from transgenic mice to provide the genetic proof that defective CFTR compromises both uptake and clearance of internalized Pseudomonas aeruginosa. We demonstrate that the proteostasis regulator cysteamine, which rescues the function of the most common F508del-CFTRmutant and hence reduces lung inflammation in CF patients, can also repair the defects of CFmacrophages, thus restoring both bacterial internalization and clearance through a process that involves upregulation of the pro-autophagic protein Beclin 1 and re-establishment of the autophagic pathway. Altogether these results indicate that cysteamine restores the function of several distinct cell types, including that of macrophages, which might contribute to its beneficial effects on CF.
AB - Cystic fibrosis (CF), the most common lethal monogenic disease in Caucasians, is characterized by recurrent bacterial infections and colonization, mainly by Pseudomonas aeruginosa, resulting in unresolved airway inflammation. CF is caused by mutations in the gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein, which functions as a chloride channel in epithelial cells, macrophages, and other cell types. Impaired bacterial handling by macrophages is a feature of CF airways, although it is still debated how defective CFTR impairs bacterial killing. Recent evidence indicates that a defective autophagy in CF macrophages leads to alterations of bacterial clearance upon infection. Here we use bone marrow-derived macrophages from transgenic mice to provide the genetic proof that defective CFTR compromises both uptake and clearance of internalized Pseudomonas aeruginosa. We demonstrate that the proteostasis regulator cysteamine, which rescues the function of the most common F508del-CFTRmutant and hence reduces lung inflammation in CF patients, can also repair the defects of CFmacrophages, thus restoring both bacterial internalization and clearance through a process that involves upregulation of the pro-autophagic protein Beclin 1 and re-establishment of the autophagic pathway. Altogether these results indicate that cysteamine restores the function of several distinct cell types, including that of macrophages, which might contribute to its beneficial effects on CF.
UR - http://www.scopus.com/inward/record.url?scp=85021704663&partnerID=8YFLogxK
U2 - 10.1038/cddis.2016.476
DO - 10.1038/cddis.2016.476
M3 - Article
C2 - 28079883
AN - SCOPUS:85021704663
SN - 2041-4889
VL - 8
JO - Cell Death and Disease
JF - Cell Death and Disease
IS - 1
M1 - e2544
ER -